ApoA-IV is the third most abundant apolipoprotein in high density lipoproteins (HDL), and the only one that circulates at appreciable concentrations in a non-lipid-associated (lipid-free) form. ApoA-IV has potent anti-atherosclerotic and anti-inflammatory properties. The aims of this project are to identify which regions of apoA-IV mediate these effects and to elucidate the mechanisms by which they exert their actions. Full length apoA-IV will be subjected to limited proteolysis. The resulting peptides will be isolated and their anti-atherosclerotic and anti-inflammatory properties assessed using established protocols. Synthetic peptides representing specific regions of apoA-IV will also be investigated. Studies will be conducted in vitro and in vivo.
For more information contact Prof Kerry-Anne Rye
© 2010 Heart Research Institute Ltd ABN 41 003 209 952